- Oral proteins and peptides, designed for non-invasive delivery of biologics through the gastrointestinal tract, are emerging as transformative solutions in drug administration due to their potential to enhance patient adherence and eliminate the need for injections in chronic disease management
- The growing demand for oral biologics is primarily driven by increasing incidences of chronic conditions such as diabetes, hormonal disorders, and gastrointestinal diseases, coupled with technological advances in drug formulation, including enzyme inhibitors and permeation enhancers that improve bioavailability
- North America dominated the oral proteins and peptides market with the largest revenue share of 39.5% in 2024, owing to strong R&D investments, a well-established biopharmaceutical industry, and early adoption of novel drug delivery platforms, particularly in the U.S., where regulatory support and clinical trial advancements are accelerating product development
- Asia-Pacific is expected to be the fastest growing region in the oral proteins and peptides market during the forecast period due to increasing healthcare expenditure, expanding patient population, and rising awareness of advanced therapeutics
- The insulin segment dominated the oral proteins and peptides market with a market share of 46.1% in 2024, driven by the surging global diabetes burden and intensive efforts to develop patient-friendly oral insulin formulations
